Skip to content
Assyro AI
FDA Orange Book ยท active-ingredient family

Fluticasone propionate; salmeterol xinafoate

Fluticasone propionate; salmeterol xinafoate: 3 brands, 5 generics; first approved Aug 24, 2000; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 5 ANDA applications approved.

Earliest patent expiry
Brands (NDA)
3
Generics (ANDA)
5
Listed patents
14
Next patent expiry
Feb 14, 2031
in 4 yr 4 mo

Brand (NDA) products

Originator applications
Ask AI
  • NDA 20879920196 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.055MG/INH;EQ 0.014MG BASE/INHPOWDERINHALATIONRx-
    0.113MG/INH;EQ 0.014MG BASE/INHPOWDERINHALATIONRx-
    0.232MG/INH;EQ 0.014MG BASE/INHPOWDERINHALATIONRx-
    0.055MG/INH;EQ 0.014MG BASE/INHPOWDERINHALATIONDiscontinued-
    0.113MG/INH;EQ 0.014MG BASE/INHPOWDERINHALATIONDiscontinued-
    0.232MG/INH;EQ 0.014MG BASE/INHPOWDERINHALATIONDiscontinued-
  • NDA 02125420063 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.045MG/INH;EQ 0.021MG BASE/INHAEROSOL, METEREDINHALATIONRx-
    0.115MG/INH;EQ 0.021MG BASE/INHAEROSOL, METEREDINHALATIONRx-
    0.23MG/INH;EQ 0.021MG BASE/INHAEROSOL, METEREDINHALATIONRx-
  • NDA 02107720003 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.1MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.25MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.5MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB

Generic (ANDA) products (5)

Abbreviated applications
Ask AI
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.1MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.25MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.5MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
  • ANDA 21446420262 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.1MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.25MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
  • ANDA 21394820213 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.1MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.25MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.5MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.1MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.25MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.5MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
  • ANDA 20889120193 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    0.1MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.25MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB
    0.5MG/INH;EQ 0.05MG BASE/INHPOWDERINHALATIONRxAB

Patent & exclusivity timeline

Protection horizon
Ask AI
202620282030203220342036203820402042TodayPatent 10195375: 2031-02-14Patent 10195375Patent 10195375*PED: 2031-08-14Patent 10195375*PEDPatent 9415008: 2034-10-06Patent 9415008Patent 9066957: 2034-10-06Patent 9066957Patent 9415008*PED: 2035-04-06Patent 9415008*PEDPatent 9066957*PED: 2035-04-06Patent 9066957*PEDPatent 10918816: 2035-12-14Patent 10918816Patent 10918816*PED: 2036-06-14Patent 10918816*PEDPatent 11969544: 2039-08-20Patent 11969544Patent 11344685: 2039-09-26Patent 11344685Patent 11969544*PED: 2040-02-20Patent 11969544*PEDPatent 11344685*PED: 2040-03-26Patent 11344685*PEDPatent 11173259: 2040-07-06Patent 11173259Patent 11173259*PED: 2041-01-06Patent 11173259*PED
Patent expiryExclusivity endToday

Listed patents

Orange Book patent file
Ask AI
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10195375in 4 yr 4 mo
Product
10195375*PEDin 4 yr 10 mo
9415008in 8 yr
ProductU-645
9066957in 8 yr
ProductU-645
9415008*PEDin 8 yr 6 mo
9066957*PEDin 8 yr 6 mo
10918816in 9 yr 2 mo
Product
10918816*PEDin 9 yr 8 mo
11969544in 12 yr 11 mo
Product
11344685in 13 yr
Product
11969544*PEDin 13 yr 5 mo
11344685*PEDin 13 yr 6 mo
11173259in 13 yr 10 mo
Product
11173259*PEDin 14 yr 4 mo

Approval history

FDA approval span
Ask AI
First approval
26 yr 8 mo ago
Most recent approval
4 mo ago

Approvals span 2000โ€“2026 across 8 FDA applications.

Brand (NDA) 338%
Generic (ANDA) 563%

Fluticasone propionate; salmeterol xinafoate: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Fluticasone propionate; salmeterol xinafoate

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo